摘要
目的:研究重组人血管内皮抑制素(rhu-Endostatin)对小鼠Lewis肺癌肿瘤生长的抑制作用,寻找其量效关系及其作用机制。方法:每只小鼠剃毛背部皮下接种Lewis肺癌细胞,待肿瘤长至100mm^3左右时,随机分为低、中、高3个剂量组,每次分别注射rhu-Endostatin5mg/(kg·d),15mg/(kg·d)或30mg/(kg·d),每天1次,连续21d。同时设置生理盐水对照组和注射用环磷酰胺[100mg/(kg·d)]治疗对照组。于第22天断颈处死小鼠,称皮下肿瘤的重量,并取脑、肺、肝、脾和肾切片做病理学检查。结果:血管内皮抑制素治疗组的曲线下面积明显小于肿瘤对照组(P<0.01)。病理切片检查显示,治疗组肿瘤有大面积的坏死,瘤周毛细血管消失。结论:rhu-Endostatin可明显抑制小鼠Lewis肺癌肿瘤的生长(高剂量组可达58.8％)、转移和新生毛细血管的形成。
Objective: To investigate the anti-tumor effect of recombinant human Endostatin (rhu-Endostatin) on the
growth of mouse Lewis lung carcinoma cells, and to elucidate the dose-effect relationship and its possible mechanism.
Methods: Lewis lung carcinoma cells were inoculated to mice (10~5/ml). When trmor size reached about 100 mm^3, the
mice were randomly divided into low, medium and high dose groups with saline and CSA [100 mg/(kg·d)] as control.
Rhu-Endostatin [5, 15, 30 mg/(kg·d)] was injected to mouse once a day for 21 days. At the 22 nd day, mice were ex-
ecuted, the tumor weights was calculated, and sections of brain, lung, liver, spleen and kidney was subjected to physio-
logical analysis. Results: Area under curve in the endostatin-treated group was obviously less than that in tamor control
group (P<0. 01). Pathological study revealed that lavge areal necrosis arose in tumor and newborn capillaries around the
tumor disappeared. Conclusion: The results revealed that rhu-Endostatin inhibited the growth, metastasis and angiogene-
sis of mouse Lewis lung carcinoma with the highest inhibition rate of 58. 8%.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
2003年第4期274-276,共3页
Chinese Journal of Cancer Biotherapy
基金
辽宁省科学技术厅(200122600l)基金
